1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

Summary

GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.

Highlights

Key Questions Answered

- How will major clinical trials of currently marketed therapies impact the future of the dyslipidemia market? Particular attention will be given to the HPS2-THRIVE and IMPROVE-IT Phase III studies of niacin and Zetia (ezetimibe).
- What role will statins play in the future of the dyslipidemia market?
- What are the clinical, regulatory, and commercial prospects of the proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) from Amgen, Sanofi/Regeneron, and Pfizer and the cholesteryl ester transfer protein (CETP) inhibitors from Eli Lilly, Merck, and Dezima Pharma?
- How will novel lipid-modulating agents, such as Esperion Therapeutic’s ETC-1002 and Cerenis Therapeutic’s CER-001, impact the dynamics of the dyslipidemia market?
- What are the key market drivers, barriers, and unmet needs that remain unaddressed by currently marketed therapies? What will remain unaddressed by the current dyslipidemia pipeline?

Key Findings

- The highest-impact driver of the dyslipidemia market will be the launch of the PCSK9 inhibitors, human monoclonal antibody biologics that will be used to treat high LDL-C in addition to statins. Therapeutic novelty combined with biologic pricing will make the PCSK9s the largest contributors to dyslipidemia market growth, even if their use is reserved for niche or high-risk cases.
- The CETP inhibitors in the late-stage pipeline have the potential to bring a novel tool to bear against high LDL-C and low HDL-C. However, their success at the regulatory level will depend heavily on their success in major Phase III cardiovascular outcomes trials, making the CETPs the wild-cards of the dyslipidemia pipeline.
- Due to the maturity of the current dyslipidemia market, new therapies will need to exploit novel mechanisms of action and/or target orphan drug targets and are more likely to be utilized as add-on therapies to existing treatments. There is a unique opportunity in the familial hypercholesterolemia arena, where effective LDL-C lowering therapies are needed that exhibit clean safety/side-effect profiles.

Scope

- Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the dyslipidemia therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 8MM dyslipidemia therapeutics market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023
1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 24
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 28
2.3 Upcoming Related Reports 28
3 Disease Overview 29
3.1 Etiology and Pathophysiology 29
3.1.1 Etiology 29
3.1.2 Pathophysiology 31
3.2 Symptoms 35
3.3 Prognosis 35
3.4 Quality of Life 35
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.2 Global and Historical Trends 37
4.2.1 US 38
4.2.2 5EU 38
4.2.3 Asia 40
4.3 Forecast Methodology 41
4.3.1 Sources Used 49
4.3.2 Forecast Assumptions and Methods 55
4.3.3 Sources Not Used 81
4.4 Prevalent Cases of Dyslipidemia 82
4.4.1 Total Prevalent Cases of Dyslipidemia 82
4.4.2 Age-Specific Total Prevalent Cases of Dyslipidemia 83
4.4.3 Sex-Specific Total Prevalent Cases of Dyslipidemia 85
4.4.4 Age-Standardized Total Prevalence of Dyslipidemia 87
4.5 Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023) 88
4.5.1 Total Prevalent Cases of Familial Hypercholesterolemia 88
4.6 Epidemiological Forecast for Increased LDL-C (2013-2023) 89
4.6.1 Total Prevalent Cases of Increased LDL-C 89
4.6.2 Age-Specific Total Prevalent Cases of Increased LDL-C 91
4.6.3 Sex-Specific Total Prevalent Cases of Increased LDL-C 93
4.6.4 Age-Standardized Total Prevalence of Increased LDL-C 95
4.7 Epidemiological Forecast for Very High TG (?500mg/dL) (2013-2023) 96
4.7.1 Total Prevalent Cases of Very High TG (?500mg/dL) 96
4.7.2 Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 98
4.7.3 Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 100
4.7.4 Age-Standardized Total Prevalence of Very High TG (?500mg/dL) 102
4.8 Discussion 103
4.8.1 Epidemiological Forecast Insight 103
4.8.2 Limitations of the Analysis 104
4.8.3 Strengths of the Analysis 105
5 Disease Management 106
5.1 Diagnosis and Treatment Overview 106
5.1.1 Diagnosis 106
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 108
5.1.3 Clinical Practice 111
5.2 US 113
5.3 France 117
5.4 Germany 119
5.5 Italy 122
5.6 Spain 125
5.7 UK 126
5.8 Japan 129
5.9 China 131
6 Competitive Assessment 134
6.1 Overview 134
6.2 Product Profiles - Major Brands 138
6.2.1 Statins 138
6.2.2 Zetia (ezetimibe) 158
6.2.3 Vytorin (simvastatin/ezetimibe) 167
6.2.4 Liptruzet (atorvastatin/ezetimibe) 171
6.2.5 Niaspan (niacin extended-release) 175
6.2.6 Kynamro (mipomersen sodium) 181
6.2.7 Juxtapid (lomitapide) 188
6.2.8 TriCor/Trilipix (fenofibrate/fenfibric acid) 193
6.2.9 Omega-3 Fatty Acids 198
6.2.10 Welchol (colesevelam HCl) and the Bile Acid Sequestrants 213
7 Unmet Need and Opportunity 219
7.1 Overview 219
7.2 LDL-C-Lowering Drugs for Statin-Intolerant and Statin-Refractory Patients 220
7.2.1 Unmet Need 220
7.2.2 Gap Analysis 221
7.2.3 Opportunity 222
7.3 Improved Diagnosis, Patient Education, and Long-term Compliance 223
7.3.1 Unmet Need 223
7.3.2 Gap Analysis 224
7.3.3 Opportunity 226
7.4 Therapies that Prevent or Reverse the Build-Up of Atherosclerotic Plaque 227
7.4.1 Unmet Need 227
7.4.2 Gap Analysis 228
7.4.3 Opportunity 229
7.5 Therapies for Patients with HoFH with Improved Side Effect Profiles 230
7.5.1 Unmet Need 230
7.5.2 Gap Analysis 231
7.5.3 Opportunity 232
8 Pipeline Assessment 233
8.1 Overview 233
8.2 Clinical Trial Mapping 237
8.2.1 Clinical Trials by Patient Population 237
8.3 Promising Drugs in Clinical Development 237
8.3.1 Alirocumab 237
8.3.2 Bococizumab 246
8.3.3 Evolocumab 251
8.3.4 Anacetrapib 260
8.3.5 Evacetrapib 268
8.3.6 TA-8995 (DEZ-001) 274
8.3.7 CER-001 280
8.3.8 ETC-1002 286
8.4 Other Drugs in Development 294
9 Current and Future Players 295
9.1 Overview 295
9.2 Trends in Corporate Strategy 300
9.3 Company Profiles 302
9.3.1 AbbVie 302
9.3.2 Aegerion Pharmaceuticals, Inc. 304
9.3.3 Amarin 306
9.3.4 Amgen 308
9.3.5 AstraZeneca 310
9.3.6 Cerenis Therapeutics Inc. 313
9.3.7 Daiichi Sankyo 315
9.3.8 Dezima Pharma 317
9.3.9 Eli Lilly 319
9.3.10 Esperion Therapeutics, Inc. 322
9.3.11 Genzyme 324
9.3.12 GlaxoSmithKline 326
9.3.13 Merck and Co. 328
9.3.14 Pfizer 331
9.3.15 Regeneron Pharmaceuticals, Inc. 333
9.3.16 Sanofi 335
10 Market Outlook 339
10.1 Global Markets 339
10.1.1 Forecast 339
10.1.2 Drivers and Barriers - Global Issues 348
10.2 United States 351
10.2.1 Forecast 351
10.2.2 Key Events 356
10.2.3 Drivers and Barriers 357
10.3 5EU 359
10.3.1 Forecast 359
10.3.2 Key Events 367
10.3.3 Drivers and Barriers 368
10.4 Japan 371
10.4.1 Forecast 371
10.4.2 Key Events 374
10.4.3 Drivers and Barriers 375
10.5 China 377
10.5.1 Forecast 377
10.5.2 Key Events 381
10.5.3 Drivers and Barriers 381
11 Appendix 384
11.1 Bibliography 384
11.2 Abbreviations 412
11.3 Methodology 420
11.4 Forecasting Methodology 420
11.4.1 Diagnosed Dyslipidemia Patients 420
11.4.2 Percent Drug-Treated Patients 421
11.4.3 Drugs Included in Each Therapeutic Class 421
11.4.4 Launch and Patent Expiry Dates 422
11.4.5 General Pricing Assumptions 423
11.4.6 Individual Drug Assumptions 424
11.4.7 Generic Erosion 431
11.4.8 Pricing of Pipeline Agents 431
11.5 Physicians and Specialists Included in this Study 432
11.6 About the Authors 434
11.6.1 Analyst 434
11.6.2 Therapy Area Director 435
11.6.3 Epidemiologist 435
11.6.4 Global Head of Healthcare 436
11.7 About GlobalData 437
11.8 Disclaimer 437

1.1 List of Tables
Table 1: Dyslipidemia: Key Metrics in Eight Major Pharmaceutical Markets 29
Table 2: Common Secondary Causes of Dyslipidemia 31
Table 3: Risk Factors and Comorbidities for Dyslipidemia 37
Table 4: Overview of the Total Prevalence of Low HDL-C in the 5EU 40
Table 5: NCEP ATP III Classification of LDL-C, TG, and HDL-C 42
Table 6: Simon Broome Diagnostic Criteria for FH 43
Table 7: LDL-C Based Definition of FH 43
Table 8: Sources of Total Prevalence Data for FH in the 8MM 44
Table 9: Sources of Total Prevalence Data for Increased LDL-C in the 8MM 45
Table 10: Sources of Total Prevalence Data for High TG (?200mg/dL) in the 8MM 46
Table 11: Sources of Total Prevalence Data for Very High TG (?500mg/dL) in the 8MM 47
Table 12: Sources of Total Prevalence Data for Low HDL-C in the 8MM 48
Table 13: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia 81
Table 14: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 82
Table 15: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013 84
Table 16: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N (Row %), 2013 86
Table 17: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 88
Table 18: 8MM, Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 90
Table 19: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, N (Row %), 2013 92
Table 20: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N (Row %), 2013 94
Table 21: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 97
Table 22: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, N (Row %), 2013 99
Table 23: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N (Row %), 2013 101
Table 24: Treatment Guidelines for Dyslipidemia 109
Table 25: Most Commonly Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2014 111
Table 26: Country Profile - US 116
Table 27: Country Profile - France 119
Table 28: Country Profile - Germany 122
Table 29: Country Profile - Italy 124
Table 30: Country Profile - Spain 126
Table 31: Country Profile - UK 128
Table 32: Country Profile - Japan 131
Table 33: Country Profile - China 133
Table 34: Leading Treatments for Dyslipidemia, 2014 138
Table 35: Statin Combination Therapies 140
Table 36: Product Profile - Lipitor 141
Table 37: Lipitor (atorvastatin) SWOT Analysis, 2014 143
Table 38: Global Sales Forecasts ($m) for Lipitor (atorvastatin), 2013-2023 144
Table 39: Product Profile - Crestor (rosuvastatin) 146
Table 40: Crestor (rosuvastatin) SWOT Analysis, 2014 148
Table 41: Global Sales Forecasts ($m) for Crestor (rosuvastatin), 2013-2023 149
Table 42: Product Profile - Zocor (simvastatin) 150
Table 43: Zocor (simvastatin) SWOT Analysis, 2014 152
Table 44: Global Sales Forecasts ($m) for Zocor (simvastatin), 2013-2023 153
Table 45: Product Profile - Livalo (pitavastatin) 154
Table 46: Livalo (pitavastatin) SWOT Analysis, 2014 157
Table 47: Product Profile - Zetia (ezetimibe) 160
Table 48: Zetia (ezetimibe) SWOT Analysis, 2014 166
Table 49: Global Sales Forecasts ($m) for Zetia (ezetimibe), 2013-2023 167
Table 50: Product Profile - Vytorin (simvastatin/ezetimibe) 168
Table 51: Vytorin (simvastatin/ezetimibe) SWOT Analysis, 2014 170
Table 52: Global Sales Forecasts ($m) for Vytorin (simvastatin/ezetimibe), 2013-2023 171
Table 53: Product Profile - Liptruzet (atorvastatin/ezetimibe) 172
Table 54: Liptruzet (atorvastatin/ezetimibe) SWOT Analysis, 2014 174
Table 55: Global Sales Forecasts ($m) for Liptruzet (atorvastatin/ezetimibe), 2013-2023 175
Table 56: Product Profile - Niaspan (niacin extended-release) 177
Table 57: Niaspan (niacin extended-release) SWOT Analysis, 2014 180
Table 58: Global Sales Forecasts ($m) for Niaspan (niacin extended-release), 2013-2023 181
Table 59: Product Profile - Kynamro (mipomersen sodium) 183
Table 60: Kynamro-Induced Changes in Lipid Parameters from Akdim et al., 2010 184
Table 61: Kynamro-Induced Changes in Lipid Parameters from Raal et al., 2010 185
Table 62: Kynamro (mipomersen) SWOT Analysis, 2014 186
Table 63: Global Sales Forecasts ($m) for Kynamro (mipomersen), 2013-2023 187
Table 64: Product Profile - Juxtapid (lomitapide) 189
Table 65: Juxtapid-Induced Dose-Responsive Changes in Lipid Parameters from Cuchel et al., 2007 190
Table 66: Juxtapid-Induced Changes in Lipid Parameters from Cuchel et al., 2013 191
Table 67: Juxtapid (lomitapide) SWOT Analysis, 2014 192
Table 68: Global Sales Forecasts ($m) for Juxtapid (lomitapide), 2013-2023 193
Table 69: A Summary of the Therapeutic Properties of Fibrates* 194
Table 70: Product Profile - TriCor (fenofibrate) and Trilipix (fenofibric acid) 195
Table 71: TriCor/Trilipix (fenofibrate/fenofibric acid) SWOT Analysis, 2014 197
Table 72: Global Sales Forecasts ($m) for TriCor/Trilipix (fenofibrate/fenofibric acid), 2013-2023 198
Table 73: Product Profile - Lovaza (omega-3 acid ethyl esters) 200
Table 74: Lovaza (omega-3 acid ethyl esters) SWOT Analysis, 2014 202
Table 75: Global Sales Forecasts ($m) for Lovaza (omega-3 acid ethyl esters), 2013-2023 203
Table 76: Product Profile - Vascepa (icosapent ethyl) 205
Table 77: Vascepa (icosapent ethyl) SWOT Analysis, 2014 207
Table 78: Global Sales Forecasts ($m) for Vascepa (icosapent ethyl), 2013-2023 208
Table 79: Product Profile - Epanova (omega-3 carboxylic acids) 209
Table 80: Epanova-Induced Changes in Blood Lipid Parameters from Kastelein et al., 2012 211
Table 81: Epanova-Induced Changes in Blood Lipid Parameters from Maki et al., 2013 211
Table 82: Epanova (omega-3 carboxylic acids) SWOT Analysis, 2014 212
Table 83: Global Sales Forecasts ($m) for Epanova (omega-3 carboxylic acids), 2013-2023 213
Table 84: Product Profile - Welchol (colesevelam HCl) 215
Table 85: Welchol-Induced Changes in Blood Glucose and Lipid Parameters from Zieve et al., 2007 216
Table 86: Welchol (colesevelam HCl) SWOT Analysis, 2014 217
Table 87: Global Sales Forecasts ($m) for Welchol (colesevelam HCl), 2013-2023 218
Table 88: Unmet Need and Opportunity in Dyslipidemia 220
Table 89: Comparison of Therapeutic Classes in Development for Dyslipidemia, 2014 236
Table 90: Product Profile - Alirocumab 240
Table 91: Alirocumab SWOT Analysis, 2014 245
Table 92: Global Sales Forecasts ($m) for Alirocumab, 2013-2023 246
Table 93: Product Profile - Bococizumab 247
Table 94: Bococizumab SWOT Analysis, 2014 250
Table 95: Global Sales Forecasts ($m) for Bococizumab, 2013-2023 251
Table 96: Product Profile - Evolocumab 253
Table 97: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 - Q1 2014 255
Table 98: Evolocumab SWOT Analysis, 2014 259
Table 99: Global Sales Forecasts ($) for Evolocumab, 2013-2023 260
Table 100: Product Profile - Anacetrapib 262
Table 101: Anacetrapib SWOT Analysis, 2014 266
Table 102: Global Sales Forecasts ($) for Anacetrapib, 2013-2023 267
Table 103: Product Profile - Evacetrapib 269
Table 104: Evacetrapib SWOT Analysis, 2014 273
Table 105: Global Sales Forecasts ($) for Evacetrapib, 2013-2023 274
Table 106: Product Profile - TA-8995 (DEZ-001) 275
Table 107: Impact of Steady-State TA-8995 on CETP and Lipid Parameters from Ford et al., 2014 276
Table 108: TA-8995 SWOT Analysis, 2014 279
Table 109: Global Sales Forecasts ($) for TA-8995, 2013-2023 280
Table 110: Product Profile - CER-001 282
Table 111: CER-001 SWOT Analysis, 2014 285
Table 112: Global Sales Forecasts ($) for CER-001, 2013-2023 286
Table 113: Product Profile - ETC-1002 288
Table 114: ETC-1002/Ezetimibe Active Comparator Trial Results 290
Table 115: ETC-1002 SWOT Analysis, 2014 292
Table 116: Global Sales Forecasts ($) for ETC-1002, 2013-2023 293
Table 117: Dyslipidemia Drugs in Development, 2014 294
Table 118: Key Companies in the Dyslipidemia Market in the 8MM, 2014 298
Table 119: AbbVie's Dyslipidemia Portfolio Assessment, 2014 303
Table 120: Aegerion's Dyslipidemia Portfolio Assessment, 2014 305
Table 121: Amarin's Dyslipidemia Portfolio Assessment, 2014 307
Table 122: Amgen's Dyslipidemia Portfolio Assessment, 2014 309
Table 123: AstraZeneca's Dyslipidemia Portfolio Assessment, 2014 312
Table 124: Cerenis' Dyslipidemia Portfolio Assessment, 2014 314
Table 125: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2014 316
Table 126: Dezima's Dyslipidemia Portfolio Assessment, 2014 318
Table 127: Eli Lilly's Dyslipidemia Portfolio Assessment, 2014 320
Table 128: Esperion's Dyslipidemia Portfolio Assessment, 2014 323
Table 129: Genzyme's Dyslipidemia Portfolio Assessment, 2014 325
Table 130: GlaxoSmithKline's Dyslipidemia Portfolio Assessment, 2014 327
Table 131: Merck's Dyslipidemia Portfolio Assessment, 2014 330
Table 132: Pfizer's Dyslipidemia Portfolio Assessment, 2014 332
Table 133: Regeneron's Dyslipidemia Portfolio Assessment, 2014 334
Table 134: Sanofi's Dyslipidemia Portfolio Assessment, 2014 337
Table 135: Global Sales Forecasts ($m) for Dyslipidemia, 2013-2023 342
Table 136: Dyslipidemia Market - Drivers and Barriers, 2014 348
Table 137: Sales Forecasts ($) for Dyslipidemia in the United States, 2013-2023 353
Table 138: Key Events Impacting Sales for Dyslipidemia in the US, 2014 356
Table 139: Dyslipidemia Market - US Drivers and Barriers, 2014 357
Table 140: Sales Forecast ($m) for Dyslipidemia in the 5EU, 2013-2023 360
Table 141: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2014 367
Table 142: Dyslipidemia Market - 5EU Drivers and Barriers, 2014 368
Table 143: National Healthcare Authorities in the 5EU Nations 368
Table 144: National Public Health Initiatives in the 5EU Nations 369
Table 145: Governmental Drug Pricing Authorities in the 5EU Nations 370
Table 146: Sales Forecasts ($) for Dyslipidemia in Japan, 2013-2023 372
Table 147: Key Events Impacting Sales for Dyslipidemia in Japan, 2014 374
Table 148: Dyslipidemia Market - Japan Drivers and Barriers, 2014 375
Table 149: Sales Forecasts ($) for Dyslipidemia in China, 2013-2023 378
Table 150: Key Events Impacting Sales for Dyslipidemia in China, 2014 381
Table 151: Dyslipidemia Market - China Drivers and Barriers, 2014 381
Table 152: Key Launch Dates 422
Table 153: Key Patent Expiries 422
Table 154: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 434

1.2 List of Figures
Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 83
Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013 85
Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N, 2013 86
Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ?20 Years, by Sex, 2013 87
Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 89
Figure 6: 8MM, Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 91
Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013 93
Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N, 2013 95
Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDL-C (?115mg/dL to ?160mg/dL)* (%), Ages ?20 Years, by Sex, 2013 96
Figure 10: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 98
Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013 100
Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N, 2013 101
Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (?500mg/dL) (%), Ages ?20 Years, by Sex, 2013 102
Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2013-2023 236
Figure 15: Dyslipidemia Therapeutics - Clinical Trials by Indication and Lipid Biomarker, 2014 237
Figure 16: Global Sales of Branded Products for Dyslipidemia by Company, 2013-2023 299
Figure 17: Company Portfolio Gap Analysis in Dyslipidemia, 2013-2023 300
Figure 18: Global Sales for Dyslipidemia by Country, 2013-2023 344
Figure 19: Global Sales for Dyslipidemia by Drug Class, 2013-2023 345
Figure 20: Global Sales Forecast for PCSK9 mAbs, 2015-2023 346
Figure 21: Projected Global Sales of Dyslipidemia Drugs by Year, 2013-2023 347
Figure 22: Sales for Dyslipidemia in the United States by Drug Class, 2013-2023 355
Figure 23: Composite Sales for Dyslipidemia in the 5EU by Drug Class, 2013-2023 362
Figure 24: Sales Breakdown for the 5EU Markets, 2013-2023 363
Figure 25: 5EU Country Sales, Segmented by Drug Class, 2013-2023 364
Figure 26: High-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023 365
Figure 27: Low-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023 366
Figure 28: Sales for Dyslipidemia in Japan by Drug Class, 2013-2023 373
Figure 29: Sales for Dyslipidemia in China by Drug Class, 2013-2023 380

Companies Mentioned
AbbVie
Aegerion Pharmaceuticals, Inc.
Amarin
Amgen
AstraZeneca
Cerenis Therapeutics Inc.
Daiichi Sankyo
Dezima Pharma
Eli Lilly
Esperion Therapeutics, Inc.
Genzyme
GlaxoSmithKline
Merck and Co.
Pfizer
Regeneron Pharmaceuticals, Inc.
Sanofi

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Blood cholesterol monitors Market Research Report 2016

Global Blood cholesterol monitors Market Research Report 2016

  • $ 2850
  • Industry report
  • September 2016
  • by 9Dimen Research

2016 Global Blood cholesterol monitors Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Blood cholesterol monitors industry, focusing ...

2016 Global and Chinese Cholesterol Industry Market Research Report

2016 Global and Chinese Cholesterol Industry Market Research Report

  • $ 2800
  • Industry report
  • September 2016
  • by Prof Research

The 'Global and Chinese Cholesterol Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Cholesterol industry with a focus on the Chinese ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.